• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Ignyte Acquisition Corp. (Amendment)

    5/9/22 4:29:00 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials
    Get the next $IGNY alert in real time by email
    SC 13G/A 1 tm2214961d1_sc13ga.htm SC 13G/A

     

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G/A

    (Amendment No. 1)

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO §240.13d-2

     

    Ignyte Acquisition Corp.
    (Name of Issuer)

     

    Common Stock, $0.0001 par value
    (Title of Class of Securities)

     

    G45175H106
    (CUSIP Number)

     

    May 2, 2022
    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ¨ Rule 13d-1 (b)

     

      x Rule 13d-1 (c)

     

      ¨ Rule 13d-1 (d)

     

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    (Continued on following page(s))
    Page 1 of 6 Pages

     

     

     

     

     

     

     

     

    CUSIP No. G45175H106 13G Page 2 of 6 Pages

      

    1

    NAME OF REPORTING PERSON
    Nemean Asset Management, LLC

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨
    (b) x

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION
    Florida

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    5

    SOLE VOTING POWER
    -0-

     

    6

    SHARED VOTING POWER
    -0-

     

    7

    SOLE DISPOSITIVE POWER
    -0-

     

    8

    SHARED DISPOSITIVE POWER
    -0-

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    -0-

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES   (SEE INSTRUCTIONS) ¨

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
    0.00%

     

    12

    TYPE OF REPORTING PERSON
    CO

     

           

     

     

      

    CUSIP No. G45175H106 13G Page 3 of 6 Pages

     

    1

    NAME OF REPORTING PERSON
    Steven M. Oliveira

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨
    (b) x

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION
    U.S.A.

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    5

    SOLE VOTING POWER
    -0-

     

    6

    SHARED VOTING POWER
    -0-

     

    7

    SOLE DISPOSITIVE POWER
    -0-

     

    8

    SHARED DISPOSITIVE POWER
    -0-

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    -0-

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES   (SEE INSTRUCTIONS) ¨

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
    0.00%

     

    12

    TYPE OF REPORTING PERSON
    IN

     

           

     

     

     

    CUSIP No. G45175H106 13G Page 4 of 6 Pages

     

    Item 1.

     

      (a) Name of Issuer: Ignyte Acquisition Corp., a Delaware corporation (the "Company").

     

      (b) Address of Issuer's Principal Executive Offices:

     

    The Company's principal executive offices are located at 640 5th Avenue, 4th Floor, New York, NY 10019.

     

    Item 2.

     

      (a) Name of Person Filing: Nemean Asset Management, LLC
          Steven Oliveira

     

      (b) Address of Principal Business Office or if none, Residence:

     

    Nemean Asset Management, LLC:

    225 Via Palacio

    Palm Beach Gardens, FL 33418

     

    Steven Oliveira:

    c/o Nemean Asset Management, LLC

    225 Via Palacio

    Palm Beach Gardens, FL 33418

     

      (c) Citizenship: Nemean Asset Management, LLC – Florida

    Steven Oliveira – U.S.A.

     

      (d) Title of Class of Securities:  Common Stock, $0.0001 par value

     

      (e) CUSIP Number:  G45175H106

     

      Item 3. Not Applicable

     

      Item 4. Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a) Amount Beneficially Owned:

     

    Nemean Asset Management, LLC – 0.

     

    Steven Oliveira – 0.

     

    Steven Oliveira has voting and dispositive power over the securities owned by Nemean Asset Management, LLC.

     

      (b) Percent of Class:

     

    Nemean Asset Management, LLC – 0.00%

     

    Steven Oliveira – 0.00%

     

    At the close of business of May 2, 2022, the reporting persons did not beneficially own any shares of common stock of the Issuer.  

     

     

    CUSIP No. G45175H106 13G Page 5 of 6 Pages

     

      (c) Number of shares as to which such person has:

     

      (i) sole power to vote or to direct the vote:

     

    Nemean Asset Management, LLC – 0.

     

    Steven Oliveira – 0.

     

      (ii) shared power to vote or to direct the vote:

     

    Nemean Asset Management, LLC – 0.

     

    Steven Oliveira – 0.

     

      (iii) sole power to dispose or to direct the disposition of:

     

    Nemean Asset Management, LLC – 0.

     

    Steven Oliveira – 0.

     

      (iv) shared power to dispose or to direct the disposition of:

     

    Nemean Asset Management, LLC – 0.

     

    Steven Oliveira – 0.

     

      Item 5. Ownership of Five Percent or Less of a Class:

    X 

      Item 6. Ownership of More than Five Percent on Behalf of Another Person: Not Applicable

     

      Item 7. Identification and Classification of Subsidiary Which Acquired the Securities: Not Applicable

     

      Item 8. Identification and Classification of Members of the Group: Not Applicable

     

      Item 9. Notice of Dissolution of Group: Not Applicable

     

      Item 10. Certifications: Not Applicable

      

     

     

     

    CUSIP No. G45175H106 13G Page 6 of 6 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    May 4, 2022

      

      NEMEAN ASSET MANAGEMENT, LLC
           
           
           
      By: /s/ Steven Oliveira  
        Name:  Steven Oliveira  
        Title:    Authorized Signatory  
           
           
           
           
        /s/ Steven Oliveira  
        Steven Oliveira  

      

     

     

     

     

     

      

    Get the next $IGNY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IGNY

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IGNY
    SEC Filings

    View All

    SEC Form 8-K filed by Ignyte Acquisition Corp.

    8-K - Peak Bio, Inc. (0001834645) (Filer)

    2/6/24 4:09:01 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    SEC Form 8-K filed by Ignyte Acquisition Corp.

    8-K - Peak Bio, Inc. (0001834645) (Filer)

    1/29/24 5:08:05 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    Ignyte Acquisition Corp. filed SEC Form 8-K: Unregistered Sales of Equity Securities

    8-K - Peak Bio, Inc. (0001834645) (Filer)

    1/3/24 5:08:00 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    $IGNY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Lamond Stephen J bought 5,600 shares, increasing direct ownership by 39% to 19,850 units (SEC Form 4)

    4 - Peak Bio, Inc. (0001834645) (Issuer)

    9/28/23 4:05:23 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    Lamond Stephen J bought 14,250 shares (SEC Form 4) (Amendment)

    4/A - Peak Bio, Inc. (0001834645) (Issuer)

    9/28/23 4:05:04 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    SEC Form 4: Huh Hoyoung bought 45,000 shares, increasing direct ownership by 0.54% to 8,382,742 units

    4 - Peak Bio, Inc. (0001834645) (Issuer)

    9/25/23 4:05:03 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    $IGNY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Peak Bio Co., Ltd. to List on NASDAQ Following Successful Business Combination with Ignyte Acquisition Corp.

    Combined Company Scheduled to Commence Trading on NASDAQ Under the Ticker Symbol "PKBO" Peak Bio Co., Ltd. ("Peak Bio"), a clinical-stage biopharmaceutical company focused on developing the next-generation of therapeutics to treat oncology and inflammatory diseases, today announced the completion of its business combination (the "Business Combination") with Ignyte Acquisition Corp. (NASDAQ:IGNY) ("Ignyte"), a special purpose acquisition company. The transaction was approved at a special meeting of Ignyte's stockholders held on October 25, 2022 (the "Special Meeting"). Ignyte's stockholders also voted to approve all other proposals presented at the Special Meeting. Ignyte's Board of Direct

    11/2/22 7:30:00 AM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    Ignyte Acquisition Corp. Stockholders Approve Proposed Business Combination with Peak Bio

    Transaction Expected to Close on October 31, 2022 Ignyte Acquisition Corp. ("Ignyte") (NASDAQ:IGNY), a publicly traded special purpose acquisition company, today announced that Ignyte's stockholders have approved its proposed business combination (the "Business Combination") with Peak Bio Co., Ltd. ("Peak Bio") at a Special Meeting of its stockholders held on October 25, 2022 (the "Special Meeting"). The Special Meeting to be held on October 31, 2022 has been canceled. Approximately 75% of the votes cast at the Special Meeting, representing approximately 75% of Ignyte's outstanding shares of common stock entitled to vote at the Special Meeting, were cast in favor of the proposal to approv

    10/27/22 8:05:00 AM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    Peak Bio and Ignyte Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Oncology and Inflammation Company

    - Company to be led by Hoyoung Huh, M.D. Ph.D., serial entrepreneur / investor with notable public and private biotech board positions - $25 million private investment in public equity ("PIPE") with participation from leading healthcare institutional investor, Palo Alto Investors (PAI) with additional participation from Peak Bio's CEO, Hoyoung Huh, MD, Ph.D. - Differentiated pipeline includes next generation Neutrophil Elastase Inhibitor targeting AATD / ARDS and robust preclinical ADC oncology platform utilizing Antibody Drug Conjugates - Anticipated cash at closing expected to fully fund the company through 2024 allowing for multiple milestones in ADC program and interim Phase II for A

    4/28/22 4:32:00 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    $IGNY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Lamond Stephen J bought 5,600 shares, increasing direct ownership by 39% to 19,850 units (SEC Form 4)

    4 - Peak Bio, Inc. (0001834645) (Issuer)

    9/28/23 4:05:23 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    Lamond Stephen J bought 14,250 shares (SEC Form 4) (Amendment)

    4/A - Peak Bio, Inc. (0001834645) (Issuer)

    9/28/23 4:05:04 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    SEC Form 4: Huh Hoyoung bought 45,000 shares, increasing direct ownership by 0.54% to 8,382,742 units

    4 - Peak Bio, Inc. (0001834645) (Issuer)

    9/25/23 4:05:03 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    $IGNY
    Financials

    Live finance-specific insights

    View All

    Peak Bio and Ignyte Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Oncology and Inflammation Company

    - Company to be led by Hoyoung Huh, M.D. Ph.D., serial entrepreneur / investor with notable public and private biotech board positions - $25 million private investment in public equity ("PIPE") with participation from leading healthcare institutional investor, Palo Alto Investors (PAI) with additional participation from Peak Bio's CEO, Hoyoung Huh, MD, Ph.D. - Differentiated pipeline includes next generation Neutrophil Elastase Inhibitor targeting AATD / ARDS and robust preclinical ADC oncology platform utilizing Antibody Drug Conjugates - Anticipated cash at closing expected to fully fund the company through 2024 allowing for multiple milestones in ADC program and interim Phase II for A

    4/28/22 4:32:00 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    $IGNY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Ignyte Acquisition Corp.

    SC 13D - Peak Bio, Inc. (0001834645) (Subject)

    3/21/23 5:30:30 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    SEC Form SC 13G filed by Ignyte Acquisition Corp.

    SC 13G - Peak Bio, Inc. (0001834645) (Subject)

    2/28/23 4:01:06 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials

    SEC Form SC 13G/A filed by Ignyte Acquisition Corp. (Amendment)

    SC 13G/A - Peak Bio, Inc. (0001834645) (Subject)

    2/14/23 3:39:04 PM ET
    $IGNY
    Consumer Electronics/Appliances
    Industrials